Geratherm operates as a niche player in specialized medical devices with strong German manufacturing credentials and developed-market distribution networks. The company has recently undergone portfolio reorientation toward higher-margin professional medical devices while maintaining consumer product leadership in thermometry and vital sign monitoring.
Cyborg Score Rationale
Geratherm demonstrates solid fundamentals with diversified product portfolio, established international presence in 60 countries, and recent operating turnaround momentum. However, the small market cap (€21.9M) and limited scale create execution risks, though the company appears financially stable with positive earnings.
Top Insights
Recently achieved operating turnaround with solid revenue growth entering 2025
Portfolio reorientation toward higher-value professional medical devices alongside consumer products
MRI-compatible incubator technology (nomag®IC advanced) represents differentiated offering in neonatal care
Significant undervaluation at P/E of 11.54 with €0.35 EPS, trading below 1-year target price of €6.00
Named Competitors
Vital Signs Monitoring — Large-scale vital signs and patient monitoring systems
Clinical Thermometry — Consumer and clinical thermometers and vital sign devices
Respiratory Diagnostics — Pulmonary function testing and cardiopulmonary stress testing systems
Recent Developments
(January 2025) Started year with strong momentum - solid revenue growth and operating turnaround
(2024) Successfully reoriented product portfolio toward professional medical devices
(2025) Continuing strategic focus on higher-margin specialized diagnostics and neonatal care systems
Open the full interactive Geratherm Medical AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.